ѰҽÎÊÒ©Íø >> ÕýÎÄ
HIVÍ»ÆÆËÞÖ÷ϸ°ûµÄ¡°·¨±¦¡±
À´Ô´£ºÑ°Ò½ÎÊÒ©Íø¡¡Ñ°Ò½ÎÊÒ©Íø
Ñо¿ÈËÔ±ÔÚÎÄÕÂÖнâÊÍ˵£¬HIVÕâÑùµÄ²¡¶¾º¬ÓÐÒ»ÖÖ²¡¶¾¸ÐȾÒò×Ó(viral infectivity factor£¬Vif)£¬VifÊDz¡¶¾ÌÓ¹ýÈËÌåϸ°ûµÄÌìÈ»¿¹²¡¶¾ÎïÖÊAPOBEC3GËù±ØÐèµÄ¡£Îª´ì°ÜÈËÌåµÄ¿¹²¡¶¾ÎïÖÊ£¬VifÐèÒªÓëһϵÁе°°×Ï໥×÷ÓÃÀ´ÐÞÊκͽµ½âAPOBEC3G¡£»ôÆÕ½ð˹¹«¹²ÎÀÉúѧԺ·Ö×Ó΢ÉúÎïÓëÃâÒßѧϵµÄ¸±½ÌÊÚXiao-Fang Yu²©Ê¿ºÍËûµÄͬÊÂʶ±ð³öÕâһϵÁе°°×¾ÍÊÇCullin5¡¢Elongins B ºÍ CÒÔ¼° Rbx1¡£×éºÏÔÚÒ»Æð£¬Õâ4ÖÖµ°°×ÐγÉÒ»¸ö½Ð×ö·ºËØE3 Á¬½Óø(ubiquitin E3 ligase £¬Cul5-SCF)µÄµ°°×¸´ºÏÌ壬Õâ¸ö¸´ºÏÌåÓëVif ºÍ APOBEC3GÏ໥×÷Óá£
¡°ÎÒÃÇÒѾ·¢ÏÖʹHIVÄÜսʤϸ°ûµÖ¿¹Òò×Ó¡¢¸ÐȾÈËÌåϸ°ûµÄÖÚ¶à»·½ÚÖеÄÐÂÒ»»·¡£¡±Yu²©Ê¿Ëµ¡£¡°ÕâЩÓйص°°×µÄʶ±ð£¬½«Ê¹ÎÒÃÇ¿ÉÒÔ¿ª·¢³ö·ÀÖÎHIV¸ÐȾµÄÐÂÒ©ºÍÐÂÁÆ·¨¡£¡±
ͨ¹ýһϵÁÐʵÑéÊÒʵÑ飬YuµÄÑо¿Ð¡×é½øÒ»²½·¢ÏÖ£¬Cul5-SCF¹¦ÄÜµÄÆÆ»µ»áʹHIVµÄ¸ÐȾÐÔ½µµÍ£¬ÒÖÖÆAPOBEC3G¼°Æä±£»¤×÷ÓõÄÄÜÁ¦¼õÈõ¡£µ±¹ýÁ¿±í´ïµÄCul5 Í»±ä»ùÒòÓëAPOBEC3G×éºÏÔÚÒ»Æðʱ£¬HIVµÄ¸ÐȾÐÔ½µµÍÁË90%¡£
Yu²©Ê¿ºÍËûµÄͬÊÂXianghui Yu²©Ê¿¡¢ Yunkai Yu²©Ê¿¡¢Bindong Liu ²©Ê¿ºÍKun Luo²©Ê¿ÕýÔÚ½øÒ»²½Ì½Ë÷VifºÍ Cul5 ¸´ºÏÌåÏ໥×÷ÓõĻúÖÆÒÔ¼°×è¶ÏVif¹¦ÄÜÓÉ´ËÏû³ýHIV¸ÐȾÐԵIJßÂÔ¡£
ÕâÆªÎÄÕÂÓÉÃÀ¹ú¹ú¼ÒÑо¿×ÊÔ´ÖÐÐÄ×ÊÖú¡£ÊÔ¼ÁÓÉÃÀ¹úNIHµÄ°¬×̲¡Ñо¿·Ö²¿µÄ°¬×̲¡Ñо¿ÊÔ¼Á¼Æ»®Ìṩ¡£ÌâĿΪ"Induction of Ubiquitination and Degradation of APOBEC3G by HIV-1 Vif-Cul5-SCF"£¬×÷ÕßΪXianghui Yu, Yunkai Yu, Bindong Liu, Kun Luo, Wei Kong, Panyong MaoºÍ Xiao-Fang Yu¡£
ÍÆ¼öÔĶÁ
¼²²¡´óÈ«¸ü¶à>>
½¡¿µÍ¼Æ×
- ÓÑÇéÁ´½Ó